Dr. Mary Jackson is currently a Professor of Bacteriology in the Department of Microbiology, Immunology, and Pathology at Colorado State University. She earned a Bioengineering degree and an MSc. Degree from the National School of Agronomy, Rennes, France, in 1994, and a Ph.D. in Biochemistry and Cellular and Molecular Biology from the Pasteur Institute, Paris, France, in 1998. 
Her research focuses on the elucidation of critical pathways leading to the biosynthesis and export of (glyco)lipids, fatty acids, and polysaccharides in Mycobacterium tuberculosis and other mycobacterial pathogens of clinical interest to inform novel therapeutic strategies. 
Dr. Jackson has published over 185 peer-reviewed scientific articles and serves on numerous grant review panels for the National Institutes of Health and other Federal, private, and non-profit funding agencies globally. 
 

---

Celso A Reis is the Head of the Glycobiology in Cancer group at i3S-Institute for Research and Innovation in Health, University of Porto, Portugal. He serves as a member of the Board of Directors of i3S and on the Board of IGO. He is a Professor at the Institute of Biomedical Sciences, University of Porto, and an invited Professor at the Faculty of Medicine of the University of Porto. Celso A Reis has published 227 peer-reviewed papers with over 15400 citations and with an H-index of 56 (Scopus). He is the author of several book chapters and patents. Currently, he leads an international multidisciplinary team working on glycobiology in human diseases focusing on cancer. His lab investigates the molecular mechanisms controlling glycosylation in cancer and the role of glycans during carcinogenesis and tumor progression. He has made several contributions to the development of novel strategies to improve cancer diagnosis, prognosis, and patient stratification. These include the studies on the role of glycosyltransferases regulating the biosynthesis of several glycans involved in cancer, such as those controlling critical steps on mucin-type O-glycosylation and N-glycosylation, with impact in cancer invasion and metastasis, as well as the tumor microenvironment.

---

Alice L. Yu, MD, PhD, is an Academician of Academia Sinica, Taiwan. She is a Distinguished Chair Professor & Deputy Director of the Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital and Professor Emeritus at the University of California in San Diego.  
As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target glycolipids worldwide. She has continued to improve the efficacy of anti-GD2 immunotherapy through international collaboration. Her group has demonstrated the adverse impact of Globo H expression on the outcome of patients with hepatoma, cholangiocarcinoma, and gallbladder cancer. She also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and angiogenic factor, providing rationales for the ongoing development of Globo H-targeted immunotherapeutics. 
She has received many awards, including the Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium (USA) in 2016, The 55th Academic Award from the Ministry of Education (Taiwan), Year 2000 "Key to Life" Award, Leukemia & Lymphoma Society (USA), etc.

---

Dr. Juge has 25-year expertise in the molecular studies of carbohydrate-protein recognition in gut biology and microbiology, and food biotechnology. She is a deputy leader of the Gut Microbes and Health Institute Strategic Programme at the Quadram Institute Bioscience (QIB, Norwich, UK) and an elected fellow of the Royal Society of Biology. Her previous research at Marseille University (France) and Carlsberg Research Institute (Copenhagen, Denmark) focused on the structure-function relationships of plant and microbial carbohydrate-active enzymes and their potential biotechnological application. Since joining QIB in 2007, she has led a Research Group focusing on the Glycobiology of Host-Microbe interactions in the gut. Currently, her group focuses mainly on defining how gut bacteria adapt to the intestinal mucosal environment and the role of mucin glycans in the crosstalk between the gut bacteria and the host. Their work uncovered novel sialic acid metabolism pathways in gut bacteria, contributing to their fitness in the mucus niche and communication with the host. They are also interested in how cell-surface glycosylation of gut symbionts influences the host immune response. Her Lab is involved in initiatives promoting Glycosciences in Europe, such as Sweet Crosstalk or Glytunes multidisciplinary European Training Networks or CarboMet academic-industry network.

 

---

Professor Yasuhiko Kizuka has been a researcher at Disease Glycomics Team, RIKEN, led by Dr. Naoyuki Taniguchi (2009-2017). He has joined Gifu University (Japan) as an Associate Professor since 2017, and is currently the Director and Professor of Integrated Glyco-Molecular Science Center, Institute for Glyco-core Research (iGCORE) at Gifu University.
Professor Kizuka’s glyco-related contributions include discovery of novel mode of catalytic action of glycosyltransferases, elucidation of glycosyltransferase structures and development of glycosyltransferase inhibitors. His Research Interests are (1) Regulation of glycosyltransferase activity; (2) Substrate protein selectivity of glycosyltransferases; (3) Physiological functions of N-glycan branches.

---

Dr. Ryan Weiss began his diverse scientific training by earning his B.S. in Chemistry in 2008 at Point Loma Nazarene University in San Diego, CA, USA. He then received his Ph.D. in Chemistry in 2015 at the University of California, San Diego, under the supervision of Prof. Yitzhak Tor, where he studied the design, synthesis, and application of small molecule antagonists of heparin- and heparan sulfate-protein interactions. As an NIH K12 postdoctoral fellow in Prof. Jeffrey Esko’s group at the Department of Cellular and Molecular Medicine at the University of California, San Diego, his research focused on utilizing whole-genome screening methods to investigate the regulation of heparan sulfate biosynthesis. Dr. Weiss began his independent career as an assistant professor at the Complex Carbohydrate Research Center at the University of Georgia in January 2021. Research in the Weiss Laboratory focuses on studying the structure, function, and regulation of complex carbohydrates in human biology and disease. In addition, his lab is dedicated to developing pharmacological and cell-based tools to aid in the discovery of novel targets and approaches for modulating glycan assembly in relevant human disorders.

---

Salomé Pinho is the coordinator of the research group "Immunology, Cancer & GlycoMedicine" at the Institute for Research and Innovation in Health (i3S) at the University of Porto, Portugal, and affiliated Professor at the Medical Faculty of the University of Porto, Portugal. She developed her Ph.D. research at the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) and Boston University Medical School, MA, USA. She performed her postdoctoral work at IPATIMUP-University of Porto in the cancer glycobiology field. Early in her career, Dr. Pinho established a research line focusing on glycoimmunology in Inflammatory Bowel Disease. Her group focuses on understanding the role of post-translational modifications by glycosylation in the regulation of key proteins´ functions involved in cancer and chronic inflammatory conditions, envisioning potential clinical applications. 
She is the Principal Investigator of several national/international grants in cancer glycobiology and inflammatory diseases. She received the Young Investigator Award from the European Association for Cancer Research and was recently distinguished by the Society for Glycobiology with the 2020 Glycobiology Significant Achievement Award.

 

---

Professor Wong received his B.S. and M.S. degrees from National Taiwan University, and Ph.D. (1982) in Chemistry from MIT. He then worked at Harvard University as a postdoctoral fellow, became an assistant professor at Texas A&M University in 1983, and became a professor in 1987. He was Professor and Ernest W. Hahn Chair in Chemistry at the Scripps Research Institute (1989–2006), Director of Genomics Research Center (2003–2006), and President of Academia Sinica (2006-2016). He is currently the Scripps Family Chair Professor of Chemistry at The Scripps Research Institute with a joint appointment at Genomics Research Center, Academia Sinica.  
Professor Wong receives numerous awards, including the U.S. Presidential Green Chemistry Challenge Award, the ACS Claude Hudson Award in Carbohydrate Chemistry, Creative Work in Synthetic Organic Chemistry, and the Cope Medal, the Wolf Prize in Chemistry. He is a member of Academia Sinica, the American Academy of Arts and Sciences, and the U.S. National Academy of Sciences.
His research interests are in the field of chemical biology and synthetic chemistry, including the synthesis of complex carbohydrates and glycoproteins associated with disease progression. He is the author of over 700 publications (H-index 144) and 100 patents.

---

Dr. Sriram Neelamegham is a UB Distinguished Professor of Chemical & Biological Engineering, Biomedical Engineering, and Medicine at the State University of New York-Buffalo. His laboratory works at the interface of engineering and medicine, with applications in studies of human disease mechanics. Such work falls under the umbrella of "Systems Glycobiology," where high-throughput experimentation and mathematical modeling are coupled to describe the interplay between the competing glycoEnzymes that regulate cellular glycosylation patterns. Prof. Neelamegham has published over 140 research articles, book chapters, and patents. He receives the NIH Independent Scientist award, the 2015 State University of New York Chancellor's Award for Excellence in Scholarship and Creative Activities, and the 2018 Schoellkopf medal from the Western New York American Chemical Society. He is an Elected Fellow of the American Institute of Biological and Medical Engineering (AIMBE) and Biomedical Engineering Society (BMES). He has served on NIH advisory panels and editorial boards of various journals. He is currently the Discussion Leader developing the Symbol Nomenclature for Glycans (SNFG) at the NCBI-glycans resource. Before moving to Buffalo. Prof. Neelamegham received his Ph.D. in Chemical Engineering/Bioengineering from the Rice University and completed his post-doctoral training at the Baylor College of Medicine. 

---

Professor Matthew Pratt received a B.S. in Biochemistry and Mathematics from the University of Arizona in 1999, where he worked for Robin Polt on glycosylation reactions and the synthesis of glycosylated analogs of enkephalin peptides. He then moved to Carolyn Bertozzi' s lab at the University of California Berkeley and focused on the synthesis of complex carbohydrates and the development of chemical tools to analyze glycosylation, receiving a Ph.D. in Chemistry in 2004. He was then an American Cancer Society Postdoctoral Fellow in Tom Muir' s lab at Rockefeller University, where he developed technologies to control proteins in living cells and for the incorporation of modifications into semi-synthetic proteins. He joined the faculty at the Department of Chemistry and Biological Sciences at USC in 2009. His research focuses on the development of bioorthogonal chemical reporters and synthetic proteins to investigate the role of posttranslational modifications, with a particular interest in O-GlcNAc modification.

---

Dr. Kiyoko F. Aoki-Kinoshita became involved in glycoinformatics after working in a bioinformatics software company between 2000-2004 as a senior software engineer. She joined the Bioinformatics Center at Kyoto University first as a post-doctoral fellow and later as an assistant professor until 2006. She developed several machine learning methods for modeling glycan recognition patterns by glycan-binding proteins. She joined Soka University in 2006, where she has been developing RINGS (http://www.rings.t.soka.ac.jp), a freely-available Web resource of data mining tools for glycan analysis. Since 2014, she has been developing the international glycan repository, GlyTouCan (http://www.glytoucan.org), built for assigning unique accession numbers to all glycan structures and monosaccharide compositions (Aoki-Kinoshita et al., NAR, 2016).
Moreover, as of April 2017, she has been PI of a project developing the GlyCosmos Portal (https://glycosmos.org) as an extension of GlyTouCan, which aims to integrate glycomics data with other omics fields (Yamada et al., Nat. Methods, 2020). GlyCosmos is a member of the GlySpace Alliance, which aims to maintain and share glycan-related data under the FAIR guidelines openly.  She has also been working with the international glycoscience community to develop various educational and informational resources to provide life-science researchers with better accessibility to glycosciences.

---

Dr. Daniel Bojar is a tenure-track assistant professor at the Wallenberg Centre for Molecular and Translational Medicine & the Department of Chemistry and Molecular Biology at the University of Gothenburg in Sweden, focusing on machine learning and data science in the field of glycobiology. He obtained his Ph.D. in mammalian synthetic biology at ETH Zurich and continued his postdoctoral training in computational biology at MIT & Harvard University. His group develops and applies methods to discover sequence-to-function associations and biological roles of glycans via a broad set of approaches from machine learning, data science, and bioinformatics. Daniel was awarded a Branco Weiss Fellowship - Society in Science, as well as a Foresight Fellowship, and was recognized as a "Rising Star" by the journal Advanced Science. He was also featured on the 2022 Forbes 30 Under 30 Europe list for work in Science & Healthcare.

---

Dr. Akihiro Fujita obtained his doctoral degree from the Graduate School of Engineering at Soka University in 2022. He is one of the key developers of GlyTouCan, the international glycan repository. His research focused on the quantitative comparison of glycans using a substitution matrix based on the three-dimensional structures of monosaccharides. Currently, he serves as an assistant professor at the same university. Fujita's research revolves around the following areas: 1. In silico methods for glycan structure comparison: He employs chemoinformatics and bioinformatics techniques to compare glycan structures. This approach enhances the understanding of glycan functionality and interactions. 2. Development of glycan structure repositories and tools: Fujita is actively involved in the development of repositories that aggregate and manage glycan information. Additionally, he contributes to the creation of tools that aid researchers in glycan analysis and prediction.

---

Dr. Morihisa Fujita is a Professor at Institute for Glyco-core Research (iGCORE), Gifu University. He received his Ph.D. in 2006 at the Graduate School of Life and Environmental Science, The University of Tsukuba. Then he joined the Research Institute for Glycoscience, National Institute of Advanced Industrial Science and Technology (AIST) as a postdoctoral fellow. He worked as a postdoctoral fellow at the University of Geneva, Switzerland in 2006. He joined the Research Institute for Microbial Diseases, Osaka University as a postdoctoral fellow in 2007. He became a Specially Appointed Assistant Professor at Osaka University in 2008 and an Assistant Professor in 2012. He moved to Jiangnan University, China, as a Professor at the Key Laboratory of Carbohydrate Chemistry and Biotechnology in 2014. In 2022, he got his current position. His research interests focus on the biosynthesis, transport, and engineering of glycoproteins (Dev. Cell (2021) 56: 1195; J. Cell Biol. (2023) 222: e202208159).

---

Dr. Daniel Kolarich is a research leader at the Institute for Glycomics, Griffith University, Queensland, Australia. His group is using Mass Spectrometry based techniques to understand the role of cell surface glycoconjugates, such as glycoproteins and glycolipids, in cell communication, cell signalling, host-pathogen interactions, and diseases such as cancer. Specific research interests include analytical tool development for glycomics and glycoproteomics, Vertebrata phyloglycomics, erythropoiesis, blood products, and stem cell biology, as well as applying glycomics and glycoproteomics to understand better the role of glycoconjugates in cancer and infectious diseases. 

Originally from Vienna, Austria, he had the chance to learn from great mentors and scientists, from Vienna, where he received his education and Ph.D. via Sydney at Macquarie University and Berlin at the Max-Planck-Institute of Colloids and Interfaces before he finally landed at the Gold Coast to join the Institute for Glycomics. He has published over 140 peer-reviewed articles, is the vice president of the Australian Glycoscience Society, and is dedicated to promoting and integrating glycosciences.

---

Dr. Malaker is an Assistant Professor in the Department of Chemistry at Yale University. Her laboratory is focused on establishing methods and technology to study mucins, a class of densely O-glycosylated extracellular proteins, by MS. Additionally, the laboratory studies mucins in a biological context since these proteins play integral, yet poorly understood, roles in numerous diseases. Prior to her appointment at Yale, she received her B.S. from the University of Michigan in Biochemistry and Anthropology-Zoology. Dr. Malaker then went on to receive her Ph.D. in Chemistry from the University of Virginia in the laboratory of Professor Donald Hunt. She continued to investigate the role of aberrant glycosylation in cancer as an NIH postdoctoral fellow in Professor Carolyn Bertozzi’s laboratory at Stanford University before starting at Yale in 2021. Since starting her independent career, she has been the recipient of multiple awards, including the ASMS Research Award, RSC Chemistry Biology Interface Division Horizon Prize, ASBMB Early Career Faculty Award, and Rising Stars in Proteomics: 40 under 40. She also serves as the U.S. Representative to the IGO and is co-chairing the second Human Glycoproteomics Initiative study.

---

Dr. Giuseppe Palmisano is an Associate Professor at the Institute of Biomedical Sciences in Brazil and Macquarie University in Australia. During his Ph.D. at the University of Bari, he developed a method for analyzing protein phosphorylation in mitochondrial respiratory chain complexes. Later, during his postdoctoral training at the University of Southern Denmark, he focused on mass spectrometry-based methods to study protein post-translational modifications (PTMs) in pathophysiological systems. He developed a technique for analyzing sialylated glycopeptides and enriching specific PTMs such as O-GlcNAcylated and cysteine-oxidized peptides. These methods were applied to various biological samples and diseases, including plasma, microparticles, exosomes, diabetes, cancer, and infectious diseases. Currently, his research focuses on developing strategies to analyze PTMs, applying systems biology approaches to understand biological networks, and discovering biomarkers. His teaching activities involve courses on biochemistry, molecular biotechnology, mass spectrometry-based proteomics, and the application of systems biology in health and disease.

---

Associate Professor Morten Thaysen-Andersen heads the Analytical Glycoimmunology at Macquarie University, Sydney, Australia. Additionally, he was recently recruited as Visiting Professor at Nagoya University, Japan, to set up a Glycoproteomics lab at the prestigious Institute for Glyco-core Research (iGCORE). Across the two laboratories, his glycobiology-focused research program aims to advance our understanding of the human innate immune system and immune-related diseases, including microbial infections, inflammation, and cancer. His team develops and applies novel glycomics and glycoproteomics technologies using advanced mass spectrometry while drawing on analytical tools in protein and carbohydrate chemistry and methods in immunology, structural biology, microbiology, and molecular and cell biology to unravel fundamental glycobiological processes within the innate immune system.

---

Dr. Issaku Yamada is the Head of Glycoinformatics at the Noguchi Institute in Tokyo. He is responsible for developing a database containing GlycoNAVI (https://glyconavi.org), the International Glycan Structure Repository called GlyTouCan, and the glycoscience web portal called GlyCosmos. These freely available web resources support the research in glycoscience. He has also developed WURCS, the Web3 Unique Representation of Carbohydrate Structures, that can represent every glycan structure. WURCS is essential for developing the GlyTouCan system. Additionally, he has developed the WURCSFramework as a WURCS handling tool and WURCS-related tools such as GlycanBuilder2, GlycanBuilder4Web, and GlycanFormatConverter, which are basic software tools for glycoscience research. Moreover, he has integrated data from life science fields, specifically glycan structures between Protein Data Bank (PDB) and GlyTouCan, using developing software such as PDB2Glycan and MolWURCS. His laboratory focuses on studying the information science of structures of glycans and proteins as well as related data.

---

Professor Mingliang Ye obtained his Ph.D. under the supervision of Prof. Hanfa Zou at the Dalian Institute of Chemical Physics (DICP), Chinese Academy of Science (CAS), in 2001 and worked as a postdoctoral fellow under the supervision of Prof. Norman Dovichi at the University of Washington, USA (2001.11-2003.3), and Prof. Reudi Aebersold at the Institute for System Biology, USA (2003.3-2004.10). In November of 2004, he returned to China, and now he is a full professor in DICP and deputy director of CAS Key Laboratory of Separation Science for Analytical Chemistry. He published more than 200 peer-reviewed papers in SCI journals. He won Excellent Young Scientist Funding awarded by the National Natural Science Foundation of China in 2015. Currently, his research is mainly focused on developing new methods for analyzing protein post-translational modifications and identifying target proteins of diverse ligands. For the analysis of protein glycosylation, his team aims to develop a robust and sensitive platform to analyze site-specific glycoforms at the proteomics scale, which is achieved by developing and integrating the new methods for specific enrichment, LC-MS/MS analysis and spectra interpretation of glycopeptides.

---

Dr. Wen-Feng Zeng is a senior postdoctoral researcher at the Max-Planck Institute of Biochemistry in Munich. He is a computer scientist with research interests that include deep learning, algorithm design, and software engineering for computational proteomics and glycoproteomics. Dr. Zeng has developed glycan-first glycopeptide search engine, the pGlyco series, which can quickly identify glycopeptides with large glycan libraries, including modified glycans. He is also the developer of the first deep learning model for predicting MS/MS fragments of peptides, called pDeep. This model was subsequently modularized into a deep learning framework called AlphaPeptDeep, which is capable of predicting various properties of peptides, such as the HLA-binding affinity of immunopeptides. Prior to joining the Max-Planck Institute of Biochemistry in 2020, Dr. Zeng received his Ph.D. in computer science from the Institute of Computing Technology (ICT), Chinese Academy of Sciences, in 2017. From 2017 to 2020, he worked as an assistant professor at ICT.

---